Skip to main content
Home > BC Innovations > Strategy

Chronological Index of : Strategy

 Current Issue
  • Figure 1: New kinase inhibitors approved in U.S. by year

    Translational Notes: A conversation with Jeffrey Settleman Figure 1. New kinase inhibitors approved in U.S. by year. Counts for 2014 exclude Chugai Pharmaceutical Co. Ltd.'s Alecensa alectinib, a small molecule …

    Published on 10/2/2014
  • Table 1: Piloting progress in MS

    Translational Notes: Progressive thinking in MS Table 1. Piloting progress in MS. In the first stage of a 5-year initiative, the International Progressive MS Alliance has awarded approximately €75,000 ($95,640) to …

    Published on 10/2/2014
  • A conversation with Jeffrey Settleman

    SciBX spoke with Genentech's Jeffrey Settleman about resistance mechanisms against kinase inhibitors used to treat cancer and what should be done to tackle the problem.

    Published on 10/2/2014
  • Progressive thinking in MS

    The International Progressive MS Alliance is pushing for advances in progressive MS-an understudied form of the disease-by funding 22 projects in the pilot phase of its 5-year, €22 million ($28 million) initiative.

    Published on 10/2/2014
  • Canadian accelerant

    Two Canadian venture firms and a government-funded program have launched Canada's first national health science accelerator, Accel-Rx, to reignite local VC interest in funding early stage biotechs.

    Published on 9/25/2014
  • The FDA's push for better biomarkers

    The FDA is calling on stakeholders to help define a path for validating and approving biomarkers to enable their use in drug development.

    Published on 9/18/2014
  • Figure 1: Investing in the brain

    Translational Notes: Buckets of money for the brain Figure 1. Investing in the brain. (I) Number of public-private partnerships (PPPs) announced for neurology or cancer indications. Data include double counting as …

    Published on 9/11/2014
  • Figure 2: Neurology indications for PPPs formed since 2011

    Translational Notes: Buckets of money for the brain Figure 2. Neurology indications for PPPs formed since 2011. Data include double counting as some PPPs include multiple indications. Percentages are out of the total…

    Published on 9/11/2014
  • A conversation with Miguel Barbosa

    SciBX talked with Janssen's VP and head of immunology research and scientific partnership strategy about rethinking how to attack inflammatory bowel disease.

    Published on 9/11/2014
  • Buckets of money for the brain

    A few years ago, many companies threw in the towel on neurological diseases because poor understanding of their biology made R&D too risky. The field is finally receiving increased private and public funding, but some …

    Published on 9/11/2014
  • Table 1: Druggable projects

    Translational Notes: Funding forgotten proteins Table 1. Druggable projects. The NIH has allocated $5.8 million to fund 7 research projects that explore the biology of GPCRs, ion channels, kinases and nuclear …

    Published on 9/4/2014
  • Table 1: Allied Minds startups based in the life sciences

    Translational Notes: Meeting of the minds Table 1. Allied Minds startups based in the life sciences. Source: Allied Minds Startup Technology concept Products Origin of technology Biotectix LLC Next-generation …

    Published on 9/4/2014
  • Funding forgotten proteins

    A new NIH program is looking to fund understudied members of druggable protein classes by supporting exploratory projects at risk of being passed over because of a lack of preliminary data.

    Published on 9/4/2014
  • Meeting of the minds

    Allied Minds has partnered with Bristol-Myers Squibb to form Allied-Bristol Life Sciences LLC and can now add therapeutics to its portfolio of academia-based startups.

    Published on 9/4/2014
  • Table 1: Comparison of current awards to support nontraditional funding methods

    Translational Notes: Getting researchers off the grant treadmill Table 1. Comparison of current awards to support nontraditional funding methods. Source: NIH NIH Director's Awards National Cancer Institute …

    Published on 8/28/2014
  • Getting researchers off the grant treadmill

    The National Cancer Institute has created a generous seven-year award designed to ease the grant-writing burden for 'outstanding investigators'. Now the institute needs to ensure that the program is not just easier …

    Published on 8/28/2014
  • Industrial strength for Sanford-Burnham

    GSK executive Perry Nisen has joined Sanford-Burnham as CEO and plans to apply his industry know-how to accelerate drug development at the institute.

    Published on 8/28/2014
  • AstraZeneca taps the Cambridge wellspring

    AstraZeneca has unveiled plans for its R&D center and global headquarters in Cambridge, U.K. -- the next major step in the pharma's strategy to improve pipeline productivity to help it recover growth and regain ground …

    Published on 8/21/2014
  • Dementia public-private partnerships

    Translational Notes: AD mission in the U.K. Table 1. Dementia public-private partnerships. Selected public-private partnerships focused on dementia research initiated over the past five years. Date Title Companies…

    Published on 7/24/2014
  • Dementia research initiatives in the U.K.

    Translational Notes: AD mission in the U.K. Table 2. Dementia research initiatives in the U.K. Select U.K.-based dementia research initiatives launched during the past year. Alzheimer's Research UK is contributing a …

    Published on 7/24/2014
  • AD mission in the U.K.

    The U.K. government is responding to calls for a dementia therapy by 2025 by securing nearly L120 million (US $205 million) from U.K.-based organizations for a series of research initiatives spanning discovery to the …

    Published on 7/24/2014
  • Table 1: Innovation Fund award recipients

    Translational Notes: Partnering in pediatrics Table 1. Innovation Fund award recipients. The Innovation Fund is managed by Cincinnati Children's Center for Technology Commercialization. Source: Cincinnati Children's…

    Published on 7/17/2014
  • Partnering in pediatrics

    Rare pediatric diseases are getting a boost from Alexion Pharmaceuticals, who recently announced a research collaboration with Cincinnati Children's Hospital Medical Center.

    Published on 7/17/2014
  • CQDM: Canada on the brain

    The Quebec Consortium for Drug Discovery and Brain Canada have announced at least C$10 million (US$9.2 million) in funding for a new program to develop tools for pharma partners to accelerate the discovery of …

    Published on 6/12/2014
  • Table 1: Daiichi Sankyo's cardiovascular and endocrine/metabolic disease pipelines

    Translational Notes: Sanford-Burnham goes fourth Table 1. Daiichi Sankyo's cardiovascular and endocrine/metabolic disease pipelines. The therapies that Daiichi Sankyo Co. Ltd. (Tokyo:4568) has in its pipelines to …

    Published on 6/5/2014

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993